Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- CureApp’s Therapeutic App Makes Mark in PIII Alcohol Reduction Study
February 14, 2024
- Ono, Shattuck Ink Drug Discovery Collab on Bifunctional Fusion Proteins
February 14, 2024
- Takeda Earns US Nod for Oral EoE Drug after Resubmission
February 14, 2024
- Otsuka Cuts 2023 Profit Guidance after AD Agitation Trial Miss
February 14, 2024
- Otsuka’s AVP-786 Fails in PIII Alzheimer’s Agitation Study
February 14, 2024
- Manufacturing Change OK’ed for Januvia, Glactiv to Address Nitrosamine Impurities
February 13, 2024
- Chugai’s PNH Med Bags World’s 1st Approval in China
February 9, 2024
- Medac Poised to Cement Japan Foothold in RA, Eyes Rare Disease Launch Too: CEO
February 9, 2024
- Mounjaro Logs 5.6 Billion Yen in Q3 YTD despite Curbed Shipments: Mitsubishi
February 8, 2024
- Kowa Snags Japan Rights to Nicox’s Eye Drop Asset for Glaucoma
February 8, 2024
- Kyowa Kirin Snares Japan Rights to BridgeBio’s Skeletal Dysplasias Drug
February 8, 2024
- Kyowa Kirin’s FY2023 Sales Up by 2-Digits, Operating Profit Hits Record High
February 8, 2024
- Nick Eshkenazi to Join Astellas Top Management as Digital Chief
February 8, 2024
- Fluticasone Nasal Spray under Shipment Curbs Due to Quake, Middle East Unrest
February 8, 2024
- Quake-Hit Santen Plant to Fully Go Back Online in March
February 8, 2024
- Oncolys Forms Oncolytic Virus Sales Collab with Fujifilm in Japan
February 8, 2024
- Japan Ethical Drug Sales Up 0.8% in December: Crecon
February 8, 2024
- 2,000 Patients Receiving Leqembi in US, 4 Times the Number on Wait List: Eisai
February 7, 2024
- CEO Bids Farewell to Mitsubishi Chemical after Group Revamp
February 7, 2024
- Keytruda Tops Japan Sales Ranking for 4th Month in January: Encise
February 7, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…